MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Public ClinicalTrials.gov record NCT01501487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).
Study identification
- NCT ID
- NCT01501487
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Interventions
- TAC chemotherapy Drug
- TC chemotherapy Drug
- Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy Drug
- TCH chemotherapy Drug
- T + trastuzumab followed by CEF + trastuzumab Drug
- Dose dense AC followed by T + trastuzumab Drug
- Dose dense AC followed by T + trastuzumab + pertuzumab Drug
- PTH followed by dose dense AC of FEC Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2011
- Primary completion
- Jan 31, 2016
- Completion
- May 31, 2017
- Last update posted
- Jun 27, 2018
2011 – 2017
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama, Mitchell Cancer Institute | Mobile | Alabama | 36688 | — |
| Morton Plant Mease Health Care | Clearwater | Florida | 33756 | — |
| University of Miami | Miami | Florida | 33124 | — |
| University of South Florida Breast Cancer Program | Tampa | Florida | 33613 | — |
| Helen Ellis Memorial Hospital | Tarpon Springs | Florida | 34689 | — |
| Eastchester Center for Cancer Care | The Bronx | New York | 10469 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43212 | — |
| University of Oklahoma, Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Texas Health, Plano Cancer Institute | Plano | Texas | 75093 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01501487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2018 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01501487 live on ClinicalTrials.gov.